Theralizumab  (Synonyms: TGN1412; TAB08)

Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

CD28

Theralizumab (5 μg/mL, 4 days) increases CD4+ T-cell division in PBMCs following high-density (HD) preculture, and induces release of inflammatory cytokines^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Theralizumab (0.1-2 mg/kg, i.v.) induces lymphopenia and human cytokine release in humanized mice model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

940  [NCBI]

P10747

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.62 kDa

906068-56-2

Liquid

Colorless to light yellow

[Theralizumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Flow cytometry analysis of U266 cells labelling CD28 with Theralizumab at 20 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
• 
  Immobilized Human CD28 Protein, His Tag can bind Theralizumab. The EC₅₀ for this effect is 15.30 ng/mL.

• [1]. Thomas Hünig. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account. FEBS J. 2016 Sep;283(18):3325-34.  [Content Brief]

  [2]. Dmitry Tyrsin, et al. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. Jul-Aug 2016;34(4 Suppl 98):45-8.  [Content Brief]

  [3]. Weißmüller S, et al. TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. PLoS One. 2016 Mar 9;11(3):e0149093.  [Content Brief]

  [4]. Hussain K, et al. Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood. 2015 Jan 1;125(1):102-10.  [Content Brief]